{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:25:20Z","timestamp":1793305520092,"version":"4.5.0"},"reference-count":205,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["NRF-2020R1A5A2017323"],"award-info":[{"award-number":["NRF-2020R1A5A2017323"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002531","name":"Kyungpook National University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002531","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Pharm. Res."],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Paclitaxel (PTX) is a standard-of-care antineoplastic agent that stabilizes microtubules. However, its clinical utility is limited by dose limiting toxicities (e.g., myelosuppression and neuropathy), influencing decades of formulation development. Therefore, this review aims to analyze formulation strategies developed to address the three primary limitations. First, solvent-free formulations (e.g., albumin-bound PTX) mitigated the solvent-related toxicity and nonlinear pharmacokinetics of Cremophor EL-based PTX, improving the safety profile by eliminating hypersensitivity reactions. Second, intravenous formulations using liposomes or polymeric micelles for mitigating dose limiting toxicities via prolonged circulation and enhanced tumor retention demonstrated inconsistent clinical translation. Recently, active targeting platforms aimed to keep PTX largely inactive systemically while promoting mechanism-triggered delivery or tumoral uptake are under preclinical evaluation to expand the therapeutic index. Third, poor oral bioavailability, attributed to P-glycoprotein (P-gp)-mediated efflux and first-pass metabolism, was addressed via two strategies: gut-specific P-gp inhibition and lipid-based bypass formulations; however, interpatient absorption variability remains limited. In this review, decades of formulation research, tracing the evolution of PTX from a challenging molecule to a versatile therapeutic platform, were synthesized, highlighting the effect of addressing key biopharmaceutical and toxicity limitations in expanding its therapeutic index. Additionally, we examined the factors contributing to the frequent failure of passive targeting strategies to separate tumor exposure from systemic toxicity in human solid tumors. In conclusion, understanding PTX formulation strategies may facilitate future therapies to adopt flexible administration routes, incorporate biomarker-guided decision-making, and achieve controlled systemic exposure to reduce intrinsic dose-limiting toxicities.<\/jats:p>","DOI":"10.1007\/s12272-026-01609-w","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T18:51:58Z","timestamp":1775847118000},"page":"500-533","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Recent paclitaxel formulation strategies: expanding the therapeutic index by addressing biopharmaceutical and toxicity limitations"],"prefix":"10.1007","volume":"49","author":[{"given":"Jihoon","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Koo","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4564-709X","authenticated-orcid":false,"given":"Im-Sook","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"1609_CR1","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s12935-024-03415-0","volume":"24","author":"AI Alalawy","year":"2024","unstructured":"Alalawy AI (2024) Key genes and molecular mechanisms related to paclitaxel resistance. Cancer Cell Int 24:244. https:\/\/doi.org\/10.1186\/s12935-024-03415-0","journal-title":"Cancer Cell Int"},{"key":"1609_CR2","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.tips.2024.08.001","volume":"45","author":"NE Andersen","year":"2024","unstructured":"Andersen NE, Boehmerle W, Huehnchen P, Stage TB (2024) Neurofilament light chain as a biomarker of chemotherapy-induced peripheral neuropathy. Trends Pharmacol Sci 45:872\u2013879. https:\/\/doi.org\/10.1016\/j.tips.2024.08.001","journal-title":"Trends Pharmacol Sci"},{"key":"1609_CR3","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1093\/annonc\/mdu025","volume":"25","author":"A Awada","year":"2014","unstructured":"Awada A, Bondarenko IN, Bonneterre J, Nowara E, Ferrero JM, Bakshi AV, Wilke C, Piccart M (2014) A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). Ann Oncol 25:824\u2013831. https:\/\/doi.org\/10.1093\/annonc\/mdu025","journal-title":"Ann Oncol"},{"key":"1609_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.addr.2020.06.018","volume":"158","author":"YH Bae","year":"2020","unstructured":"Bae YH, Park K (2020) Advanced drug delivery 2020 and beyond: perspectives on the future. Adv Drug Deliv Rev 158:4\u201316. https:\/\/doi.org\/10.1016\/j.addr.2020.06.018","journal-title":"Adv Drug Deliv Rev"},{"key":"1609_CR5","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.3390\/ph18101550","volume":"18","author":"K Baek","year":"2025","unstructured":"Baek K, Jin SG (2025) Solidification materials and technology for solid self-emulsifying drug delivery systems. Pharmaceuticals 18:1550. https:\/\/doi.org\/10.3390\/ph18101550","journal-title":"Pharmaceuticals"},{"key":"1609_CR6","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.2337\/dbi18-0052","volume":"68","author":"J Bai","year":"2019","unstructured":"Bai J, Liu F (2019) The cGAS-cGAMP-STING pathway: a molecular link between immunity and metabolism. Diabetes 68:1099\u20131108. https:\/\/doi.org\/10.2337\/dbi18-0052","journal-title":"Diabetes"},{"key":"1609_CR7","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2217\/nnm-2018-0313","volume":"14","author":"MA Barkat","year":"2019","unstructured":"Barkat MA, Beg S, Pottoo FH, Ahmad FJ (2019) Nanopaclitaxel therapy: an evidence based review on the battle for next-generation formulation challenges. Nanomedicine 14:1323\u20131341. https:\/\/doi.org\/10.2217\/nnm-2018-0313","journal-title":"Nanomedicine"},{"key":"1609_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/tpj.2010.19","volume":"11","author":"TK Bergmann","year":"2011","unstructured":"Bergmann TK, Brasch-Andersen C, Green H, Mirza M, Pedersen RS, Nielsen F, Skougaard K, Wihl J, Keldsen N, Damkier P, Friberg LE, Peterson C, Vach W, Karlsson MO, Br\u00f8sen K (2011) Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J 11:113\u2013120. https:\/\/doi.org\/10.1038\/tpj.2010.19","journal-title":"Pharmacogenomics J"},{"key":"1609_CR9","doi-asserted-by":"publisher","first-page":"18844","DOI":"10.1021\/jacs.2c04944","volume":"144","author":"A Bordat","year":"2022","unstructured":"Bordat A, Boissenot T, Ibrahim N, Ferrere M, Lev\u00eaque M, Potiron L, Denis S, Garcia-Argote S, Carvalho O, Abadie J, Cailleau C, Pieters G, Tsapis N, Nicolas J (2022) A polymer prodrug strategy to switch from intravenous to subcutaneous cancer therapy for irritant\/vesicant drugs. J Am Chem Soc 144:18844\u201318860. https:\/\/doi.org\/10.1021\/jacs.2c04944","journal-title":"J Am Chem Soc"},{"key":"1609_CR10","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1007\/s12325-019-00909-6","volume":"36","author":"O Borg\u00e5","year":"2019","unstructured":"Borg\u00e5 O, Henriksson R, Bjermo H, Lilienberg E, Heldring N, Loman N (2019) Maximum tolerated dose and pharmacokinetics of paclitaxel micellar in patients with recurrent malignant solid tumours: a dose-escalation study. Adv Ther 36:1150\u20131163. https:\/\/doi.org\/10.1007\/s12325-019-00909-6","journal-title":"Adv Ther"},{"key":"1609_CR11","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0026-895X(24)12040-8","volume":"28","author":"E Brouwer","year":"2000","unstructured":"Brouwer E, Verweij J, De Bruijn P, Loos WJ, Pillay M, Buijs D, Sparreboom A (2000) Measurement of fraction unbound paclitaxel in human plasma. Drug Metab Dispos 28:1141\u20131145. https:\/\/doi.org\/10.1016\/S0026-895X(24)12040-8","journal-title":"Drug Metab Dispos"},{"key":"1609_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12917-023-03837-4","volume":"20","author":"HK Chae","year":"2024","unstructured":"Chae HK, Oh YI, Lim GH, Jung YC, Park SH, An JH, Park SM, Seo KW, Chu SN, Li Q, Youn HY (2024) Anti-cancer effects of DHP107 on canine mammary gland cancer examined through in-vitro and in-vivo mouse xenograft models. BMC Vet Res 20:3. https:\/\/doi.org\/10.1186\/s12917-023-03837-4","journal-title":"BMC Vet Res"},{"key":"1609_CR13","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/jcph.304","volume":"54","author":"N Chen","year":"2014","unstructured":"Chen N, Li Y, Ye Y, Palmisano M, Chopra R, Zhou S (2014) Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel. J Clin Pharmacol 54:1097\u20131107. https:\/\/doi.org\/10.1002\/jcph.304","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"1609_CR14","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3390\/pharmaceutics16070928","volume":"16","author":"YS Chen","year":"2024","unstructured":"Chen YS, Jin E, Day PJ (2024) Use of drug sensitisers to improve therapeutic index in cancer. Pharmaceutics 16(7):928. https:\/\/doi.org\/10.3390\/pharmaceutics16070928","journal-title":"Pharmaceutics"},{"key":"1609_CR15","first-page":"1583","volume":"6","author":"FS Chung","year":"2016","unstructured":"Chung FS, Santiago JS, De Jesus MFM, Trinidad CV, See MFE (2016) Disrupting P-glycoprotein function in clinical settings: what can we learn from the fundamental aspects of this transporter? Am J Cancer Res 6:1583\u20131598","journal-title":"Am J Cancer Res"},{"issue":"11","key":"1609_CR16","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.ccell.2022.09.016","volume":"40","author":"R Colombo","year":"2022","unstructured":"Colombo R, Rich JR (2022) The therapeutic window of antibody drug conjugates: a dogma in need of revision. Cancer Cell 40(11):1255\u20131263. https:\/\/doi.org\/10.1016\/j.ccell.2022.09.016","journal-title":"Cancer Cell"},{"issue":"2","key":"1609_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11095-018-2563-6","volume":"36","author":"MBS Crombag","year":"2019","unstructured":"Crombag MBS, de Vries Schultink AHM, Koolen SLW, Wijngaard S, Joerger M, Schellens JHM, Dorlo TPC, van Erp NP, Mathijssen RHJ, Beijnen JH, Huitema ADR (2019) Impact of older age on the exposure of paclitaxel: a population pharmacokinetic study. Pharm Res 36(2):33. https:\/\/doi.org\/10.1007\/s11095-018-2563-6","journal-title":"Pharm Res"},{"key":"1609_CR18","doi-asserted-by":"publisher","first-page":"6573","DOI":"10.2174\/0929867326666191016113631","volume":"27","author":"H Cui","year":"2020","unstructured":"Cui H, Arnst K, Miller DD, Li W (2020) Recent advances in elucidating paclitaxel resistance mechanisms in non-small cell lung cancer and strategies to overcome drug resistance. Curr Med Chem 27:6573\u20136595. https:\/\/doi.org\/10.2174\/0929867326666191016113631","journal-title":"Curr Med Chem"},{"key":"1609_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/17588359231183680","volume":"15","author":"MS Dai","year":"2023","unstructured":"Dai MS, Chao TC, Chiu CF, Lu YS, Shiah HS, Jackson CG, Hung N, Zhi J, Cutler DL, Kwan R, Kramer D, Chan WK, Qin A, Tseng KC, Hung CT, Chao TY (2023) Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study. Ther Adv Med Oncol 15:1\u201310. https:\/\/doi.org\/10.1177\/17588359231183680","journal-title":"Ther Adv Med Oncol"},{"key":"1609_CR20","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1200\/jco.2005.23.16_suppl.2048","volume":"23","author":"N Damjanov","year":"2005","unstructured":"Damjanov N, Fishman MN, Steinberg JL, Fetterly GJ, Haas A, Grahn A, Lauay C, Dul JL, Sherman JW, Rubin EH (2005) Final results of a phase I study of liposome entrapped paclitaxel (LEP-ETU) in patients with advanced cancer. J Clin Oncol 23:2048. https:\/\/doi.org\/10.1200\/jco.2005.23.16_suppl.2048","journal-title":"J Clin Oncol"},{"key":"1609_CR21","doi-asserted-by":"publisher","first-page":"722","DOI":"10.2174\/138920011798357006","volume":"12","author":"RAJ Darby","year":"2011","unstructured":"Darby RAJ, Callaghan R, McMahon RM (2011) P-glycoprotein inhibition: the past, the present and the future. Curr Drug Metab 12:722\u2013731. https:\/\/doi.org\/10.2174\/138920011798357006","journal-title":"Curr Drug Metab"},{"issue":"9747","key":"1609_CR22","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, Investigators TROPIC (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747):1147\u20131154. https:\/\/doi.org\/10.1016\/S0140-6736(10)61389-X","journal-title":"Lancet"},{"key":"1609_CR23","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/cpdd.880","volume":"10","author":"VA de Weger","year":"2021","unstructured":"de Weger VA, Vermunt MAC, Stuurman FE, Burylo AM, Damoiseaux D, Hendrikx JJMA, Sawicki E, Moes JJ, Huitema ADR, Nuijen B, Rosing H, Mergui-Roelvink M, Beijnen JH, Marchetti S (2021) A Phase I dose-escalation study of low-dose metronomic treatment with novel oral paclitaxel formulations in combination with ritonavir in patients with advanced solid tumors. Clin Pharmacol Drug Dev 10:607\u2013621. https:\/\/doi.org\/10.1002\/cpdd.880","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1609_CR24","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3109\/10717544.2014.896058","volume":"22","author":"S Dokania","year":"2015","unstructured":"Dokania S, Joshi AK (2015) Self-microemulsifying drug delivery system (SMEDDS) - challenges and road ahead. Drug Deliv 22:675\u2013690. https:\/\/doi.org\/10.3109\/10717544.2014.896058","journal-title":"Drug Deliv"},{"key":"1609_CR26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1158\/1535-7163.MCT-08-0986","volume":"8","author":"C Dumontet","year":"2009","unstructured":"Dumontet C, Jordan MA, Lee FFY (2009) Ixabepilone: targeting \u03b2III-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther 8:17\u201325. https:\/\/doi.org\/10.1158\/1535-7163.MCT-08-0986","journal-title":"Mol Cancer Ther"},{"key":"1609_CR27","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/jphp.12928","volume":"71","author":"A Effinger","year":"2019","unstructured":"Effinger A, O\u2019Driscoll CM, McAllister M, Fotaki N (2019) Impact of gastrointestinal disease states on oral drug absorption - implications for formulation design - a PEARRL review. J Pharm Pharmacol 71:674\u2013698. https:\/\/doi.org\/10.1111\/jphp.12928","journal-title":"J Pharm Pharmacol"},{"key":"1609_CR28","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/ijc.24846","volume":"126","author":"ME Eichhorn","year":"2010","unstructured":"Eichhorn ME, Ischenko I, Luedemann S, Strieth S, Papyan A, Werner A, Bohnenkamp H, Guenzi E, Preissler G, Michaelis U, Jauch KW, Bruns CJ, Dellian M (2010) Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer. Int J Cancer 126:1235\u20131245. https:\/\/doi.org\/10.1002\/ijc.24846","journal-title":"Int J Cancer"},{"key":"1609_CR29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/10837450.2017.1345940","volume":"23","author":"S El Nemr","year":"2018","unstructured":"El Nemr S, Al-Najjar BY, Omer HK, Elhissi AMA, Alhnan MA (2018) Studies of the precipitation pattern of paclitaxel in intravenous infusions and rat plasma using laser nephelometry. Pharm Dev Technol 23:67\u201375. https:\/\/doi.org\/10.1080\/10837450.2017.1345940","journal-title":"Pharm Dev Technol"},{"key":"1609_CR30","doi-asserted-by":"publisher","first-page":"773","DOI":"10.2147\/OTT.S102638","volume":"10","author":"G Eslamian","year":"2017","unstructured":"Eslamian G, Wilson C, Young RJ (2017) Efficacy of eribulin in breast cancer: a short report on the emerging new data. Onco Targets Ther 10:773\u2013779. https:\/\/doi.org\/10.2147\/OTT.S102638","journal-title":"Onco Targets Ther"},{"key":"1609_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113017","volume":"150","author":"R Fan","year":"2022","unstructured":"Fan R, Sun W, Zhang T, Wang R, Tian Y, Zhang H, Li J, Zheng A, Song S (2022) Paclitaxel-nanocrystals-loaded network thermosensitive hydrogel for localised postsurgical recurrent of breast cancer after surgical resection. Biomed Pharmacother 150:113017. https:\/\/doi.org\/10.1016\/j.biopha.2022.113017","journal-title":"Biomed Pharmacother"},{"key":"1609_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.70245","author":"H Farah","year":"2026","unstructured":"Farah H, Kadhim-Abosaoda M, Mohaisen-Mousa H, Jyothi R, Priyadarshini-Nayak P, Janney-J B, Singh G, Singh-Chauhan A, Kumar-Mishra M (2026) Exosome-based strategies in hepatocellular carcinoma: mechanisms, immunotherapy, and clinical challenges. J Gastroenterol Hepatol. https:\/\/doi.org\/10.1111\/jgh.70245","journal-title":"J Gastroenterol Hepatol"},{"key":"1609_CR33","doi-asserted-by":"publisher","first-page":"5856","DOI":"10.1158\/1078-0432.CCR-08-1046","volume":"14","author":"GJ Fetterly","year":"2008","unstructured":"Fetterly GJ, Grasela TH, Sherman JW, Dul JL, Grahn A, Lecomte D, Fiedler-Kelly J, Damjanov N, Fishman M, Kane MP, Rubin EH, Tan AR (2008) Pharmacokinetic\/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel. Clin Cancer Res 14:5856\u20135863. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1046","journal-title":"Clin Cancer Res"},{"key":"1609_CR34","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/COC.0000000000001014","volume":"46","author":"PM Fracasso","year":"2023","unstructured":"Fracasso PM, Fisher GA, Goodner SA, Beumer JH, Egorin MJ, Fears CL, Wildi JD, Jones GJ, Pearce TE, Sikic BI (2023) A phase I trial of the ABCB1 inhibitor, oral valspodar, in combination with paclitaxel in patients with advanced solid tumors. Am J Clin Oncol 46:353\u2013359. https:\/\/doi.org\/10.1097\/COC.0000000000001014","journal-title":"Am J Clin Oncol"},{"key":"1609_CR35","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1124\/dmd.110.035394","volume":"39","author":"MN Fransson","year":"2011","unstructured":"Fransson MN, Gr\u00e9en H, Litton JE, Friberg LE (2011) Influence of CrEL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model. Drug Metab Dispos 39:247\u2013255. https:\/\/doi.org\/10.1124\/dmd.110.035394","journal-title":"Drug Metab Dispos"},{"key":"1609_CR36","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.drudis.2021.11.015","volume":"26","author":"Y Fu","year":"2021","unstructured":"Fu Y, Saraswat AL, Monpara J, Patel K (2021) Stromal disruption facilitating invasion of a \u2018nano-arsenal\u2019 into the solid tumor. Drug Discov Today 26:1132\u20131141. https:\/\/doi.org\/10.1016\/j.drudis.2021.11.015","journal-title":"Drug Discov Today"},{"key":"1609_CR37","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41416-019-0391-z","volume":"120","author":"Y Fujiwara","year":"2019","unstructured":"Fujiwara Y, Mukai H, Saeki T, Ro J, Lin YC, Nagai SE, Lee KS, Watanabe J, Ohtani S, Kim SB, Kuroi K, Tsugawa K, Tokuda Y, Iwata H, Park YH, Yang Y, Nambu Y (2019) A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. Br J Cancer 120:475\u2013480. https:\/\/doi.org\/10.1038\/s41416-019-0391-z","journal-title":"Br J Cancer"},{"key":"1609_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/antib7010014","volume":"7","author":"T F\u00fcl\u00f6p","year":"2018","unstructured":"F\u00fcl\u00f6p T, M\u00e9sz\u00e1ros T, Kozma GT, Szebeni J, J\u00f3zsi M (2018) Infusion reactions associated with the medical application of monoclonal antibodies: the role of complement activation and possibility of inhibition by factor H. Antibodies 7:14. https:\/\/doi.org\/10.3390\/antib7010014","journal-title":"Antibodies"},{"key":"1609_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25245986","volume":"25","author":"J Gallego-Jara","year":"2020","unstructured":"Gallego-Jara J, Lozano-Terol G, Sola-Mart\u00ednez RA, C\u00e1novas-D\u00edaz M, de Diego Puente T (2020) A compressive review about Taxol\u00ae: history and future challenges. Molecules 25:5986. https:\/\/doi.org\/10.3390\/molecules25245986","journal-title":"Molecules"},{"key":"1609_CR40","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1158\/1078-0432.CCR-07-4592","volume":"14","author":"ER Gardner","year":"2008","unstructured":"Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N, Hawkins MJ, Sparreboom A, Figg WD (2008) Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 14:4200\u20134205. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4592","journal-title":"Clin Cancer Res"},{"key":"1609_CR41","doi-asserted-by":"publisher","first-page":"5875","DOI":"10.3748\/wjg.v23.i32.5875","volume":"23","author":"G Giordano","year":"2017","unstructured":"Giordano G, Pancione M, Olivieri N, Parcesepe P, Velocci M, Di Raimo T, Coppola L, Toffoli G, D\u2019Andrea MR (2017) Nano albumin bound-paclitaxel in pancreatic cancer: current evidences and future directions. World J Gastroenterol 23:5875\u20135886. https:\/\/doi.org\/10.3748\/wjg.v23.i32.5875","journal-title":"World J Gastroenterol"},{"key":"1609_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1486686","volume":"15","author":"M Girdenyt\u0117","year":"2024","unstructured":"Girdenyt\u0117 M, Hu Y, Ginosyan A, Hammarlund-Udenaes M, Loryan I (2024) Formulation-dependent differences in paclitaxel distribution to anatomical sites relevant to chemotherapy-induced peripheral neuropathy. Front Pharmacol 15:1486686. https:\/\/doi.org\/10.3389\/fphar.2024.1486686","journal-title":"Front Pharmacol"},{"key":"1609_CR43","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","volume":"23","author":"WJ Gradishar","year":"2005","unstructured":"Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O\u2019Shaughnessy J (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794\u20137803. https:\/\/doi.org\/10.1200\/JCO.2005.04.937","journal-title":"J Clin Oncol"},{"key":"1609_CR44","doi-asserted-by":"publisher","first-page":"12791","DOI":"10.3390\/ijms222312791","volume":"22","author":"A Grangeon","year":"2021","unstructured":"Grangeon A, Clermont V, Barama A, Gaudette F, Turgeon J, Michaud V (2021) Determination of CYP450 expression levels in the human small intestine by mass spectrometry-based targeted proteomics. Int J Mol Sci 22:12791. https:\/\/doi.org\/10.3390\/ijms222312791","journal-title":"Int J Mol Sci"},{"key":"1609_CR45","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1093\/annonc\/mdl104","volume":"17","author":"MR Green","year":"2006","unstructured":"Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM, Bhar P, Hawkins MJ (2006) Abraxane\u00ae, a novel Cremophor\u00ae-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 17:1263\u20131268. https:\/\/doi.org\/10.1093\/annonc\/mdl104","journal-title":"Ann Oncol"},{"key":"1609_CR46","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2402713","volume":"16","author":"P Green","year":"2024","unstructured":"Green P, Schneider A, Lange J (2024) Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products. Mabs 16:2402713. https:\/\/doi.org\/10.1080\/19420862.2024.2402713","journal-title":"Mabs"},{"key":"1609_CR47","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.2147\/IJN.S287434","volume":"16","author":"G Gui","year":"2021","unstructured":"Gui G, Fan Z, Ning Y, Yuan C, Zhang B, Xu Q (2021) Optimization, characterization and in vivo evaluation of paclitaxel-loaded folate-conjugated superparamagnetic iron oxide nanoparticles. Int J Nanomedicine 16:2283\u20132295. https:\/\/doi.org\/10.2147\/IJN.S287434","journal-title":"Int J Nanomedicine"},{"key":"1609_CR48","doi-asserted-by":"publisher","first-page":"85","DOI":"10.37047\/jos.2021-81340","volume":"7","author":"\u015e G\u00fcnd\u00fcz","year":"2021","unstructured":"G\u00fcnd\u00fcz \u015e, Erdem D, G\u00fcven DC, Aksoy S, Uysal M, Karg\u0131 A, Y\u0131ld\u0131z A, Karaman \u0130, \u00d6zdo\u011fan M (2021) Ixabepilone in metastatic breast cancer: real-world experience. J Oncol Sci 7:85\u201390. https:\/\/doi.org\/10.37047\/jos.2021-81340","journal-title":"J Oncol Sci"},{"issue":"4","key":"1609_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/polym14040658","volume":"14","author":"R Haddad","year":"2022","unstructured":"Haddad R, Alrabadi N, Altaani B, Li T (2022) Paclitaxel drug delivery systems: focus on nanocrystals\u2019 surface modifications. Polymers 14(4):658. https:\/\/doi.org\/10.3390\/polym14040658","journal-title":"Polymers"},{"key":"1609_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.125082","volume":"669","author":"S Hade","year":"2025","unstructured":"Hade S, Devangan P, Bajad G, Wadate N, Satti S, Dandekar MP, Madan J (2025) Capsaicin nanocrystals burdened topical polymeric gel: an encouraging tactic for alleviation of paclitaxel-induced peripheral neuropathy. Int J Pharm 669:125082. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.125082","journal-title":"Int J Pharm"},{"key":"1609_CR51","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1038\/sj.bjc.6602479","volume":"92","author":"T Hamaguchi","year":"2005","unstructured":"Hamaguchi T, Matsumura Y, Suzuki M, Shimizu K, Goda R, Nakamura I, Nakatomi I, Yokoyama M, Kataoka K, Kakizoe T (2005) NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer 92:1240\u20131246. https:\/\/doi.org\/10.1038\/sj.bjc.6602479","journal-title":"Br J Cancer"},{"key":"1609_CR52","doi-asserted-by":"publisher","first-page":"4684","DOI":"10.1021\/acsabm.0c00599","volume":"3","author":"S Han","year":"2020","unstructured":"Han S, Li X, Zhou C, Hu X, Zhou Y, Jin Y, Liu Q, Wang L, Li X, Liu Y (2020) Further enhancement in intestinal absorption of paclitaxel by using transferrin-modified paclitaxel nanocrystals. ACS Appl Bio Mater 3:4684\u20134695. https:\/\/doi.org\/10.1021\/acsabm.0c00599","journal-title":"ACS Appl Bio Mater"},{"key":"1609_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/bcr1622","volume":"8","author":"LN Harris","year":"2006","unstructured":"Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D, Lara J, Bleiweiss I, Berry D, Ellis M, Hayes DF, Winer EP, Dressler L (2006) Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res 8:R66. https:\/\/doi.org\/10.1186\/bcr1622","journal-title":"Breast Cancer Res"},{"key":"1609_CR54","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1200\/JCO.2007.15.7636","volume":"27","author":"A Hauschild","year":"2009","unstructured":"Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, Peschel C, Schadendorf D, Garbe C, O\u2019Day S, Daud A, White JM, Xia C, Patel K, Kirkwood JM, Keilholz U (2009) Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 27:2823\u20132830. https:\/\/doi.org\/10.1200\/JCO.2007.15.7636","journal-title":"J Clin Oncol"},{"key":"1609_CR55","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1038\/bjc.2014.222","volume":"110","author":"JJMA Hendrikx","year":"2014","unstructured":"Hendrikx JJMA, Lagas JS, Wagenaar E, Rosing H, Schellens JHM, Beijnen JH, Schinkel AH (2014) Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation. Br J Cancer 110:2669\u20132676. https:\/\/doi.org\/10.1038\/bjc.2014.222","journal-title":"Br J Cancer"},{"key":"1609_CR56","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1200\/JCO.2001.19.20.4065","volume":"19","author":"A Henningsson","year":"2001","unstructured":"Henningsson A, Karlsson MO, Vigano L, Gianni L, Verweij J, Sparreboom A (2001) Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol 19:4065\u20134073. https:\/\/doi.org\/10.1200\/JCO.2001.19.20.4065","journal-title":"J Clin Oncol"},{"key":"1609_CR57","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/s0959-8049(03)00126-6","volume":"39","author":"A Henningsson","year":"2003","unstructured":"Henningsson A, Sparreboom A, Sandstr\u00f6m M, Freijs A, Larsson R, Bergh J, Nygren P, Karlsson MO (2003) Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. Eur J Cancer 39:1105\u20131114. https:\/\/doi.org\/10.1016\/s0959-8049(03)00126-6","journal-title":"Eur J Cancer"},{"issue":"15","key":"1609_CR58","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1158\/1078-0432.Ccr-18-0656","volume":"24","author":"DL Hertz","year":"2018","unstructured":"Hertz DL, Kidwell KM, Vangipuram K, Li F, Pai MP, Burness M, Griggs JJ, Schott AF, Van Poznak C, Hayes DF, Lavoie Smith EM, Henry NL (2018) Paclitaxel plasma concentration after the first infusion predicts treatment-limiting peripheral neuropathy. Clin Cancer Res 24(15):3602\u20133610. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-0656","journal-title":"Clin Cancer Res"},{"key":"1609_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114024","volume":"202","author":"DL Hertz","year":"2024","unstructured":"Hertz DL, Joerger M, Bang YJ, Mathijssen RH, Zhou C, Zhang L, Gandara D, Stahl M, Monk BJ, Jaehde U, Beumer JH (2024) Paclitaxel therapeutic drug monitoring-international association of therapeutic drug monitoring and clinical toxicology recommendations. Eur J Cancer 202:114024. https:\/\/doi.org\/10.1016\/j.ejca.2024.114024","journal-title":"Eur J Cancer"},{"key":"1609_CR60","doi-asserted-by":"publisher","first-page":"4811","DOI":"10.1158\/1078-0432.CCR-14-3222","volume":"21","author":"M Hidalgo","year":"2015","unstructured":"Hidalgo M, Plaza C, Musteanu M, Illei P, Brachmann CB, Heise C, Pierce D, Lopez-Casas PP, Menendez C, Tabernero J, Romano A, Wei X, Lopez-Rios F, Von Hoff DD (2015) SPARC expression did not predict efficacy of nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer in an exploratory analysis of the phase III MPACT trial. Clin Cancer Res 21:4811\u20134818. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-3222","journal-title":"Clin Cancer Res"},{"key":"1609_CR61","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1158\/1535-7163.MCT-07-0261","volume":"6","author":"JW Hong","year":"2007","unstructured":"Hong JW, Lee IH, Kwak YH, Park YT, Sung HC, Kwon IC, Chung H (2007) Efficacy and tissue distribution of DHP107, an oral paclitaxel formulation. Mol Cancer Ther 6:3239\u20133247. https:\/\/doi.org\/10.1158\/1535-7163.MCT-07-0261","journal-title":"Mol Cancer Ther"},{"key":"1609_CR62","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/annonc\/5.suppl_4.S3","volume":"5","author":"SB Horwitz","year":"1994","unstructured":"Horwitz SB (1994) Taxol (paclitaxel): mechanisms of action. Ann Oncol 5:S3\u2013S6","journal-title":"Ann Oncol"},{"key":"1609_CR63","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1158\/1535-7163.MCT-21-0195","volume":"20","author":"Y Hu","year":"2021","unstructured":"Hu Y, Manasrah BK, McGregor SM, Lera RF, Norman RX, Tucker JB, Scribano CM, Yan RE, Humayun M, Wisinski KB, Tevaarwerk AJ, O\u2019Regan RM, Wilke LG, Weaver BA, Beebe DJ, Si N, Burkard ME (2021) Paclitaxel induces micronucleation and activates pro-inflammatory cGAS-STING signaling in triple-negative breast cancer. Mol Cancer Ther 20:2553\u20132567. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0195","journal-title":"Mol Cancer Ther"},{"key":"1609_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00524","volume":"11","author":"S Hua","year":"2020","unstructured":"Hua S (2020) Advances in oral drug delivery for regional targeting in the gastrointestinal tract - influence of physiological, pathophysiological and pharmaceutical factors. Front Pharmacol 11:524. https:\/\/doi.org\/10.3389\/fphar.2020.00524","journal-title":"Front Pharmacol"},{"key":"1609_CR65","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00432-007-0323-9","volume":"134","author":"M Hubensack","year":"2008","unstructured":"Hubensack M, M\u00fcller C, H\u00f6cherl P, Fellner S, Spruss T, Bernhardt G, Buschauer A (2008) Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice. J Cancer Res Clin Oncol 134:597\u2013607. https:\/\/doi.org\/10.1007\/s00432-007-0323-9","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"1609_CR66","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1200\/JCO.1997.15.1.317","volume":"15","author":"MT Huizing","year":"1997","unstructured":"Huizing MT, Giaccone G, van Warmerdam LJ, Rosing H, Bakker PJ, Vermorken JB, Postmus PE, van Zandwijk N, Koolen MG, ten Bokkel Huinink WW, van der Vijgh WJ, Bierhorst FJ, Lai A, Dalesio O, Pinedo HM, Veenhof CH, Beijnen JH (1997) Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European cancer centre. J Clin Oncol 15(1):317\u2013329. https:\/\/doi.org\/10.1200\/JCO.1997.15.1.317","journal-title":"J Clin Oncol"},{"key":"1609_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154009","volume":"11","author":"M Ignatiadis","year":"2016","unstructured":"Ignatiadis M, Zardavas D, Lemort M, Wilke C, Vanderbeeken M-C, D\u2019Hondt V, Sotiriou C, Di\u00e9ras V, Baurain T, Awada A, de Azambuja D, Huitema JB, Laayoune C (2016) Feasibility study of EndoTAG-1, a tumor endothelial targeting agent, in combination with paclitaxel followed by FEC as induction therapy in HER2-negative breast cancer. PLoS ONE 11:e0154009. https:\/\/doi.org\/10.1371\/journal.pone.0154009","journal-title":"PLoS ONE"},{"key":"1609_CR68","doi-asserted-by":"publisher","first-page":"4264","DOI":"10.1111\/bph.16476","volume":"181","author":"S Im","year":"2024","unstructured":"Im S, Jeong DJ, Kim E, Choi JH, Jang HJ, Kim YY, Um JH, Lee J, Lee YJ, Lee KM, Choi D, Yoo E, Lee HS, Yun J (2024) A novel marine-derived mitophagy inducer ameliorates mitochondrial dysfunction and thermal hypersensitivity in paclitaxel-induced peripheral neuropathy. Br J Pharmacol 181:4264\u20134277. https:\/\/doi.org\/10.1111\/bph.16476","journal-title":"Br J Pharmacol"},{"key":"1609_CR70","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1021\/acs.chemrev.0c00779","volume":"121","author":"M Izci","year":"2021","unstructured":"Izci M, Maksoudian C, Manshian BB, Soenen SJ (2021) The use of alternative strategies for enhanced nanoparticle delivery to solid tumors. Chem Rev 121:1746\u20131803. https:\/\/doi.org\/10.1021\/acs.chemrev.0c00779","journal-title":"Chem Rev"},{"key":"1609_CR71","doi-asserted-by":"publisher","first-page":"4759","DOI":"10.1111\/bcp.14886","volume":"87","author":"CGCA Jackson","year":"2021","unstructured":"Jackson CGCA, Hung T, Segelov E, Barlow P, Prenen H, McLaren B, Hung NA, Clarke K, Chao T, Dai M, Yeh HT, Cutler DL, Kramer D, He J, Zhi J, Chan WK, Kwan R, Deva S (2021) Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: a randomised crossover pharmacokinetic study. Br J Clin Pharmacol 87:4759\u20134770. https:\/\/doi.org\/10.1111\/bcp.14886","journal-title":"Br J Clin Pharmacol"},{"key":"1609_CR72","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/aps.2016.105","volume":"38","author":"Y Jang","year":"2017","unstructured":"Jang Y, Chung HJ, Hong JW, Yun C, Chung H (2017) Absorption mechanism of DHP107, an oral paclitaxel formulation that forms a hydrated lipidic sponge phase. Acta Pharmacol Sin 38:133\u2013145. https:\/\/doi.org\/10.1038\/aps.2016.105","journal-title":"Acta Pharmacol Sin"},{"key":"1609_CR73","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jddst.2018.09.014","volume":"48","author":"Y Jang","year":"2018","unstructured":"Jang Y, Ko MK, Park YE, Hong JW, Lee IH, Chung HJ, Chung H (2018) Effect of paclitaxel content in the DHP107 oral formulation on oral bioavailability and antitumor activity. J Drug Deliv Sci Technol 48:183\u2013192. https:\/\/doi.org\/10.1016\/j.jddst.2018.09.014","journal-title":"J Drug Deliv Sci Technol"},{"key":"1609_CR74","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200301147","author":"ME Janson","year":"2003","unstructured":"Janson ME, de Dood ME, Dogterom M (2003) Dynamic instability of microtubules is regulated by force. J Cell Biol. https:\/\/doi.org\/10.1083\/jcb.200301147","journal-title":"J Cell Biol"},{"key":"1609_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1329636","volume":"15","author":"Q Ji","year":"2017","unstructured":"Ji Q, Zhu H, Qin Y, Zhang R, Wang L, Zhang E, Zhou X, Meng R (2017) GP60 and SPARC as albumin receptors: key targeted sites for the delivery of antitumor drugs. Front Pharmacol 15:1329636. https:\/\/doi.org\/10.3389\/fphar.2024.1329636","journal-title":"Front Pharmacol"},{"key":"1609_CR76","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/FTD.0000000000000446","volume":"39","author":"M Joerger","year":"2017","unstructured":"Joerger M, Kraff S, Jaehde U, Hilger RA, Courtney JB, Cline DJ, Jog S, Baburina I, Miller MC, Salamone SJ (2017) Validation of a commercial assay and decision support tool for routine paclitaxel therapeutic drug monitoring. Ther Drug Monit 39:617\u2013624. https:\/\/doi.org\/10.1097\/FTD.0000000000000446","journal-title":"Ther Drug Monit"},{"key":"1609_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188607","volume":"1876","author":"A Kanakkanthara","year":"2021","unstructured":"Kanakkanthara A, Miller JH (2021) \u1e9eIII-tubulin overexpression in cancer: causes, consequences, and potential therapies. BBA Rev Cancer 1876:188607. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188607","journal-title":"BBA Rev Cancer"},{"key":"1609_CR78","first-page":"1610","volume":"7","author":"MH Kang","year":"2001","unstructured":"Kang MH, Figg WD, Ando Y, Blagosklonny MV, Liewehr D, Fojo T, Bates SE (2001) The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel. Clin Cancer Res 7:1610\u20131617","journal-title":"Clin Cancer Res"},{"key":"1609_CR79","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1016\/j.yexcr.2011.04.006","volume":"317","author":"MH Kang","year":"2011","unstructured":"Kang MH, Oh SC, Lee HJ, Kang HN, Kim JL, Kim JS, Yoo YA (2011) Metastatic function of BMP-2 in gastric cancer cells: the role of PI3K\/AKT, MAPK, the NF-\u03baB pathway, and MMP-9 expression. Exp Cell Res 317:1746\u20131762. https:\/\/doi.org\/10.1016\/j.yexcr.2011.04.006","journal-title":"Exp Cell Res"},{"key":"1609_CR80","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/annonc\/mdy055","volume":"29","author":"YK Kang","year":"2018","unstructured":"Kang YK, Ryu MH, Park SH, Kim JG, Kim JW, Cho SH, Park YI, Park SR, Rha SY, Kang MJ, Cho JY, Kang SY, Roh SY, Ryoo BY, Nam BH, Jo YW, Yoon KE, Oh SC (2018) Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy. Ann Oncol 29:1220\u20131226. https:\/\/doi.org\/10.1093\/annonc\/mdy055","journal-title":"Ann Oncol"},{"key":"1609_CR81","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s13346-025-01883-z","volume":"16","author":"DW Kang","year":"2026","unstructured":"Kang DW, Connor RJ, Nekoroski T, Bitsura JAM, Kindig SK, Knowles SP, LaBarre MJ (2026) A phase I clinical study to evaluate rapid, high-volume, subcutaneous auto-injector tolerability with recombinant human hyaluronidase. Drug Deliv Transl Res 16:95\u2013107. https:\/\/doi.org\/10.1007\/s13346-025-01883-z","journal-title":"Drug Deliv Transl Res"},{"key":"1609_CR82","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/jns.12493","volume":"27","author":"S Karteri","year":"2022","unstructured":"Karteri S, Bruna J, Argyriou AA, Mariotto S, Velasco R, Alemany M, Kalofonou F, Alberti P, Dinoto A, Velissaris D, Stradella A, Cavaletti G, Ferrari S, Kalofonos HP (2022) Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel-induced peripheral neurotoxicity in breast cancer patients. J Peripher Nerv Syst 27:166\u2013174. https:\/\/doi.org\/10.1111\/jns.12493","journal-title":"J Peripher Nerv Syst"},{"key":"1609_CR83","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1200\/jco.2013.31.15_suppl.3082","volume":"31","author":"K Kato","year":"2013","unstructured":"Kato K, Mukai H, Esaki T, Ohsumi S, Hozumi Y (2013) Phase I clinical study of NK105, paclitaxel-encapsulating micelles, on a weekly schedule, in patients with malignant tumors (dose-escalation phase). J Clin Oncol 31:3082\u20133082. https:\/\/doi.org\/10.1200\/jco.2013.31.15_suppl.3082","journal-title":"J Clin Oncol"},{"key":"1609_CR84","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/jvim.12596","volume":"29","author":"C Khanna","year":"2015","unstructured":"Khanna C, Rosenberg M, Vail DM (2015) A review of paclitaxel and novel formulations including those suitable for use in dogs. J Vet Intern Med 29:1006\u20131012. https:\/\/doi.org\/10.1111\/jvim.12596","journal-title":"J Vet Intern Med"},{"key":"1609_CR85","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1158\/1078-0432.Ccr-03-0655","volume":"10","author":"TY Kim","year":"2004","unstructured":"Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, Kim NK, Bang YJ (2004) Phase I and pharmacokinetic study of Genexol-PM, a Cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 10:3708\u20133716. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-03-0655","journal-title":"Clin Cancer Res"},{"key":"1609_CR86","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4168\/aair.2016.8.2.174","volume":"8","author":"YN Kim","year":"2016","unstructured":"Kim YN, Kim JY, Kim JW, Kim JH, Kim HI, Yune S, Choi DC, Lee BJ (2016) The hidden culprit: a case of repeated anaphylaxis to Cremophor. Allergy Asthma Immunol Res 8:174\u2013177. https:\/\/doi.org\/10.4168\/aair.2016.8.2.174","journal-title":"Allergy Asthma Immunol Res"},{"key":"1609_CR87","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS1106","volume":"38","author":"SB Kim","year":"2020","unstructured":"Kim SB, Zhang Q, Sun T, Seo JH, Lee KS, Kim TY, Tong Z, Park KH, Moon YW, Wang S, Li W, Yang Y, Wang J, Wang X, Choi J, Lee JE, Yoon KE, Chung S, Xu B, Sohn J (2020) [OPTIMAL 3] A phase III trial to evaluate the efficacy and safety of DHP107 (Liporaxel, oral paclitaxel) compared to Taxol (IV paclitaxel) as first line therapy in patients with recurrent or metastatic HER2 negative breast cancer (BC) (NCT03315364). J Clin Oncol 38:TPS1106-TPS1106. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.TPS1106","journal-title":"J Clin Oncol"},{"key":"1609_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/17588359211061989","volume":"13","author":"SB Kim","year":"2021","unstructured":"Kim SB, Seo JH, Ahn JH, Kim TY, Kang SY, Sohn J, Yang Y, Park KH, Moon YW, Lim S, Kang MJ, Yoon KE, Cho HJ, Lee KS (2021) Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study). Ther Adv Med Oncol 13:1\u201312. https:\/\/doi.org\/10.1177\/17588359211061989","journal-title":"Ther Adv Med Oncol"},{"key":"1609_CR89","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.942960","volume":"12","author":"SH Kim","year":"2022","unstructured":"Kim SH, Kim KH, Hyun JW, Kim JH, Seo SS, Kim HJ, Park SY, Lim MC (2022) Blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxel-induced peripheral neuropathy in patients with gynecological cancers. Front Oncol 12:942960. https:\/\/doi.org\/10.3389\/fonc.2022.942960","journal-title":"Front Oncol"},{"key":"1609_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/toxics9100229","volume":"9","author":"I Klein","year":"2021","unstructured":"Klein I, Lehmann HC (2021) Pathomechanisms of paclitaxel-induced peripheral neuropathy. Toxics 9:229. https:\/\/doi.org\/10.3390\/toxics9100229","journal-title":"Toxics"},{"key":"1609_CR91","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.2147\/ijn.S372477","volume":"17","author":"Y Kosaka","year":"2022","unstructured":"Kosaka Y, Saeki T, Takano T, Aruga T, Yamashita T, Masuda N, Koibuchi Y, Osaki A, Watanabe J, Suzuki R (2022) Multicenter randomized open-label phase II clinical study comparing outcomes of NK105 and paclitaxel in advanced or recurrent breast cancer. Int J Nanomedicine 17:4567\u20134578. https:\/\/doi.org\/10.2147\/ijn.S372477","journal-title":"Int J Nanomedicine"},{"key":"1609_CR92","doi-asserted-by":"publisher","first-page":"4955","DOI":"10.2147\/dddt.S88023","volume":"9","author":"M Kundranda","year":"2015","unstructured":"Kundranda M, Niu J (2015) Albumin-bound paclitaxel in solid tumors: clinical development and future directions. Drug des Devel Ther 9:4955\u20134967. https:\/\/doi.org\/10.2147\/dddt.S88023","journal-title":"Drug des Devel Ther"},{"key":"1609_CR93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093997","volume":"9","author":"N Kyprianou","year":"2014","unstructured":"Kyprianou N, Yang YL, Luo XP, Xian L (2014) The prognostic role of the class III $\\beta$-tubulin in non-small cell lung cancer (NSCLC) patients receiving the taxane\/vinorebine-based chemotherapy: a meta-analysis. PLoS ONE 9:e93997. https:\/\/doi.org\/10.1371\/journal.pone.0093997","journal-title":"PLoS ONE"},{"key":"1609_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.561936","volume":"10","author":"JI Lai","year":"2020","unstructured":"Lai JI, Tseng YJ, Chen MH, Huang CYF, Chang PMH (2020) Clinical perspective of FDA approved drugs with P-glycoprotein inhibition activities for potential cancer therapeutics. Front Oncol 10:561936. https:\/\/doi.org\/10.3389\/fonc.2020.561936","journal-title":"Front Oncol"},{"key":"1609_CR95","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/JTO.0b013e3181753b4b","volume":"3","author":"CJ Langer","year":"2008","unstructured":"Langer CJ, O\u2019Byrne KJ, Socinski MA, Mikhailov SM, Le\u015bniewski-Kmak K, Smakal M, Ciuleanu TE, Orlov SV, Dediu M, Heigener D, Eisenfeld AJ, Sandalic L, Oldham FB, Singer JW, Ross HJ (2008) Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-na\u00efve advanced non-small cell lung cancer. J Thorac Oncol 3:623\u2013630. https:\/\/doi.org\/10.1097\/JTO.0b013e3181753b4b","journal-title":"J Thorac Oncol"},{"key":"1609_CR96","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s10549-007-9591-y","volume":"108","author":"KS Lee","year":"2007","unstructured":"Lee KS, Chung HC, Im SA, Park YH, Kim CS, Kim SB, Rha SY, Lee MY, Ro J (2007) Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 108:241\u2013250. https:\/\/doi.org\/10.1007\/s10549-007-9591-y","journal-title":"Breast Cancer Res Treat"},{"key":"1609_CR97","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ijpharm.2010.03.033","volume":"392","author":"JY Lee","year":"2010","unstructured":"Lee JY, Kim KS, Kang YM, Kim ES, Hwang SJ, Lee HB, Min BH, Kim JH, Kim MS (2010) In vivo efficacy of paclitaxel-loaded injectable in situ-forming gel against subcutaneous tumor growth. Int J Pharm 392:51\u201356. https:\/\/doi.org\/10.1016\/j.ijpharm.2010.03.033","journal-title":"Int J Pharm"},{"key":"1609_CR98","doi-asserted-by":"publisher","first-page":"5164","DOI":"10.7150\/jca.59794","volume":"12","author":"BX Li","year":"2021","unstructured":"Li BX, Chen XJ, Ding TJ, Liu YH, Ma TT, Zhang GL, Wang XM (2021a) Potentially overestimated efficacy of nanoparticle albumin-bound paclitaxel compared with solvent-based paclitaxel in breast cancer: a systemic review and meta-analysis. J Cancer 12:5164\u20135172. https:\/\/doi.org\/10.7150\/jca.59794","journal-title":"J Cancer"},{"key":"1609_CR99","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.actbio.2021.05.019","volume":"129","author":"H Li","year":"2021","unstructured":"Li H, Wang Y, Tang Q, Yin D, Tang C, He E, Zou L, Peng Q (2021b) The protein corona and its effects on nanoparticle-based drug delivery systems. Acta Biomater 129:57\u201372. https:\/\/doi.org\/10.1016\/j.actbio.2021.05.019","journal-title":"Acta Biomater"},{"key":"1609_CR101","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1093\/annonc\/mdr297","volume":"23","author":"SM Lichtman","year":"2012","unstructured":"Lichtman SM, Hurria A, Cirrincione CT, Seidman AD, Winer E, Hudis C, Cohen HJ, Muss HB (2012) Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Ann Oncol 23:632\u2013638. https:\/\/doi.org\/10.1093\/annonc\/mdr297","journal-title":"Ann Oncol"},{"key":"1609_CR102","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202500362","volume":"12","author":"X Lin","year":"2025","unstructured":"Lin X, Wei L, Li X, Zeng L, Tang Y, Wang H, Lu H, Li C, Wang H, Chen J, Peng Y (2025) Pia mater-penetrable lipopolymer nanoparticles for gliocyte-targeted IL-10 mRNA therapy alleviate paclitaxel-induced peripheral neuropathy. Adv Sci 12:2500362. https:\/\/doi.org\/10.1002\/advs.202500362","journal-title":"Adv Sci"},{"key":"1609_CR103","doi-asserted-by":"publisher","DOI":"10.1002\/mabi.202400413","volume":"25","author":"Z Liu","year":"2024","unstructured":"Liu Z, Koseki Y, Suzuki R, Dao ATN, Kasai H (2024) Sustained drug release from dual-responsive hydrogels for local cancer chemo\u2013photothermal therapy. Macromol Biosci 25:2400413. https:\/\/doi.org\/10.1002\/mabi.202400413","journal-title":"Macromol Biosci"},{"key":"1609_CR104","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1080\/10717544.2018.1551442","volume":"26","author":"KW Locke","year":"2019","unstructured":"Locke KW, Maneval DC, LaBarre MJ (2019) ENHANZE\u00ae drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20. Drug Deliv 26:98\u2013106. https:\/\/doi.org\/10.1080\/10717544.2018.1551442","journal-title":"Drug Deliv"},{"key":"1609_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13689-y","volume":"11","author":"S Lohard","year":"2020","unstructured":"Lohard S, Bourgeois N, Maillet L, Gautier F, F\u00e9tiveau A, Lasla H, Nguyen F, Vuillier C, Dumont A, Moreau-Aubry A, Frapin M, David L, Loussouarn D, Kerdraon D, Campone M, J\u00e9z\u00e9quel P, Juin PP, Barill\u00e9-Nion S (2020) STING-dependent paracriny shapes apoptotic priming of breast tumors in response to anti-mitotic treatment. Nat Commun 11:41. https:\/\/doi.org\/10.1038\/s41467-019-13689-y","journal-title":"Nat Commun"},{"key":"1609_CR106","doi-asserted-by":"publisher","first-page":"184","DOI":"10.30574\/gscarr.2025.22.1.0011","volume":"22","author":"AM Lonkar","year":"2025","unstructured":"Lonkar AM, Ajabe RG, Akhand VG, Katekar VA, Deshmukh NB, Deshmukh SP (2025) Formulation and evaluation of gastroretentive drug delivery system. GCS Adv Res Review 22:184\u2013194. https:\/\/doi.org\/10.30574\/gscarr.2025.22.1.0011","journal-title":"GCS Adv Res Review"},{"key":"1609_CR107","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/jco.20.01399","volume":"38","author":"CL Loprinzi","year":"2020","unstructured":"Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, Kelley MR, Lavino A, Lustberg MB, Paice JA, Schneider BP, Lavoie Smith EM, Smith ML, Smith TJ, Wagner-Johnston N, Hershman DL (2020) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol 38:3325\u20133348. https:\/\/doi.org\/10.1200\/jco.20.01399","journal-title":"J Clin Oncol"},{"key":"1609_CR108","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ijpharm.2012.08.042","volume":"453","author":"Y Lu","year":"2013","unstructured":"Lu Y, Park K (2013) Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. Int J Pharm 453:198\u2013214. https:\/\/doi.org\/10.1016\/j.ijpharm.2012.08.042","journal-title":"Int J Pharm"},{"key":"1609_CR109","doi-asserted-by":"publisher","first-page":"6313","DOI":"10.2147\/ijn.s279192","volume":"16","author":"T Lu","year":"2021","unstructured":"Lu T, Prakash J (2021) Nanomedicine strategies to enhance tumor drug penetration in pancreatic cancer. Int J Nanomedicine 16:6313\u20136328. https:\/\/doi.org\/10.2147\/ijn.s279192","journal-title":"Int J Nanomedicine"},{"key":"1609_CR110","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jcis.2024.10.075","volume":"679","author":"S Lu","year":"2025","unstructured":"Lu S, Zhou S, Xiang X, Zhang B, Xu Z, Pei Q, Xie Z (2025) Paclitaxel prodrug nanoparticles boost antitumor efficacy via hitchhiking of human serum albumin. J Colloid Interface Sci 679:144\u2013154. https:\/\/doi.org\/10.1016\/j.jcis.2024.10.075","journal-title":"J Colloid Interface Sci"},{"key":"1609_CR111","doi-asserted-by":"publisher","first-page":"99","DOI":"10.6004\/jnccn.2009.0009","volume":"7","author":"GH Lyman","year":"2009","unstructured":"Lyman GH (2009) Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw 7:99\u2013108. https:\/\/doi.org\/10.6004\/jnccn.2009.0009","journal-title":"J Natl Compr Canc Netw"},{"key":"1609_CR112","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00280-022-04443-1","volume":"90","author":"WW Ma","year":"2022","unstructured":"Ma WW, Li JJ, Azad NS, Lam ET, Diamond JR, Dy GK, Opyrchal M, Zhi J, Kramer D, Chan WK, Cutler D, Kwan R, Adjei AA, Jimeno A (2022) A phase Ib study of oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies. Cancer Chemother Pharmacol 90:7\u201317. https:\/\/doi.org\/10.1007\/s00280-022-04443-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"1609_CR113","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1021\/acs.molpharmaceut.0c00574","volume":"18","author":"Y Mai","year":"2021","unstructured":"Mai Y, Dou L, Yao Z, Madla CM, Gavins FKH, Taherali F, Yin H, Orlu M, Murdan S, Basit AW (2021) Quantification of P-glycoprotein in the gastrointestinal tract of humans and rodents: methodology, gut region, sex, and species matter. Mol Pharm 18:1895\u20131904. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c00574","journal-title":"Mol Pharm"},{"key":"1609_CR114","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1054\/bjoc.2000.1543","volume":"84","author":"MM Malingr\u00e9","year":"2001","unstructured":"Malingr\u00e9 MM, Beijnen JH, Rosing H, Koopman FJ, Jewell RC, Paul EM, Huinink WW, Schellens JHM (2001) Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer 84:42\u201347. https:\/\/doi.org\/10.1054\/bjoc.2000.1543","journal-title":"Br J Cancer"},{"key":"1609_CR115","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1586\/era.09.167","volume":"10","author":"C Marchetti","year":"2014","unstructured":"Marchetti C, Pisano C, Facchini G, Bruni GS, Magazzino FP, Losito S, Pignata S (2014) First-line treatment of advanced ovarian cancer: current research and perspectives. Expert Rev Anticancer Ther 10:47\u201360. https:\/\/doi.org\/10.1586\/era.09.167","journal-title":"Expert Rev Anticancer Ther"},{"key":"1609_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/nejm199601043340101","volume":"334","author":"WP McGuire","year":"1996","unstructured":"McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1\u20136. https:\/\/doi.org\/10.1056\/nejm199601043340101","journal-title":"N Engl J Med"},{"key":"1609_CR117","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.coph.2006.01.009","volume":"6","author":"S Modok","year":"2006","unstructured":"Modok S, Mellor H, Callaghan R (2006) Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol 6:350\u2013354. https:\/\/doi.org\/10.1016\/j.coph.2006.01.009","journal-title":"Curr Opin Pharmacol"},{"key":"1609_CR118","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1111\/cts.13003","volume":"14","author":"BS Moon","year":"2021","unstructured":"Moon BS, Park HS, Sunwoo J, Lee IH, Kim A, Moon SJ, Lee H, Son MH, Kim SB, Park SM, Woo SK, Jang JH, Kim BS, Kim JH, Kim SE, Lee H (2021) Tissue pharmacokinetics of DHP107, a novel lipid-based oral formulation of paclitaxel, in mice and patients by positron emission tomography. Clin Transl Sci 14:1747\u20131755. https:\/\/doi.org\/10.1111\/cts.13003","journal-title":"Clin Transl Sci"},{"key":"1609_CR119","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1097\/j.pain.0000000000002840","volume":"164","author":"C Mortensen","year":"2023","unstructured":"Mortensen C, Steffensen KD, Simonsen E, Herskind K, Madsen JS, Olsen DA, Iversen DB, Bergmann TK, Potteg\u00e5rd A, Stage TB (2023) Neurofilament light chain as a biomarker of axonal damage in sensory neurons and paclitaxel-induced peripheral neuropathy in patients with ovarian cancer. Pain 164:1502\u20131511. https:\/\/doi.org\/10.1097\/j.pain.0000000000002840","journal-title":"Pain"},{"key":"1609_CR120","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/bcp.14678","volume":"87","author":"M Muth","year":"2021","unstructured":"Muth M, Ojara FW, Kloft C, Joerger M (2021) Role of TDM-based dose adjustments for taxane anticancer drugs. Br J Clin Pharmacol 87:306\u2013316. https:\/\/doi.org\/10.1111\/bcp.14678","journal-title":"Br J Clin Pharmacol"},{"key":"1609_CR121","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.2147\/ijn.S114356","volume":"12","author":"I Nakamura","year":"2017","unstructured":"Nakamura I, Ichimura E, Goda R, Hayashi H, Mashiba H, Nagai D, Yokoyama H, Onda T, Masuda A (2017) An in vivo mechanism for the reduced peripheral neurotoxicity of NK105: a paclitaxel-incorporating polymeric micellar nanoparticle formulation. Int J Nanomedicine 12:1293\u20131304. https:\/\/doi.org\/10.2147\/ijn.S114356","journal-title":"Int J Nanomedicine"},{"key":"1609_CR122","first-page":"1443","volume":"39","author":"T Nakashima","year":"2012","unstructured":"Nakashima T, Kiba T, Ogawa Y, Hosokawa A, Shintani H, Okada Y, Taniguchi T, Shigeta M, Kozawa K (2012) A case of paclitaxel-induced peripheral neuropathy successfully treated with pregabalin. Gan to Kagaku Ryoho 39:1443\u20131445","journal-title":"Gan to Kagaku Ryoho"},{"key":"1609_CR123","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.addr.2020.11.008","volume":"167","author":"CI Nkanga","year":"2020","unstructured":"Nkanga CI, Fisch A, Rad-Malekshahi M, Romic MD, Kittel B, Ullrich T, Wang J, Krause RWM, Adler S, Lammers T, Hennink WE, Ramazani F (2020) Clinically established biodegradable long acting injectables: an industry perspective. Adv Drug Deliv Rev 167:19\u201346. https:\/\/doi.org\/10.1016\/j.addr.2020.11.008","journal-title":"Adv Drug Deliv Rev"},{"key":"1609_CR124","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1097\/JTO.0b013e31817c6b68","volume":"3","author":"ME O\u2019Brien","year":"2008","unstructured":"O\u2019Brien ME, Socinski MA, Popovich AY, Bondarenko IN, Tomova A, Bilynsky BT, Hotko YS, Ganul VL, Kostinsky IY, Eisenfeld AJ, Sandalic L, Oldham FB, Bandstra B, Sandler AB, Singer JW (2008) Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-na\u00efve advanced non-small cell lung cancer. J Thorac Oncol 3:728\u2013734. https:\/\/doi.org\/10.1097\/JTO.0b013e31817c6b68","journal-title":"J Thorac Oncol"},{"key":"1609_CR125","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.1200\/jco.2008.17.1579","volume":"27","author":"S O\u2019Day","year":"2009","unstructured":"O\u2019Day S, Gonzalez R, Lawson D, Weber R, Hutchins L, Anderson C, Haddad J, Kong S, Williams A, Jacobson E (2009) Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J Clin Oncol 27:5452\u20135458. https:\/\/doi.org\/10.1200\/jco.2008.17.1579","journal-title":"J Clin Oncol"},{"key":"1609_CR126","doi-asserted-by":"publisher","first-page":"569","DOI":"10.4143\/crt.2016.289","volume":"49","author":"IH Park","year":"2017","unstructured":"Park IH, Sohn JH, Kim SB, Lee KS, Chung JS, Lee SH, Kim TY, Jung KH, Cho EK, Kim YS, Song HS, Seo JH, Ryoo HM, Lee SA, Yoon SY, Kim CS, Kim YT, Kim SY, Jin MR, Ro J (2017) An open-label, randomized, parallel, phase III trial evaluating the efficacy and safety of polymeric micelle-formulated paclitaxel compared to conventional CrEL-based paclitaxel for recurrent or metastatic HER2-negative breast cancer. Cancer Res Treat 49:569\u2013577. https:\/\/doi.org\/10.4143\/crt.2016.289","journal-title":"Cancer Res Treat"},{"key":"1609_CR127","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1016\/j.apsb.2023.02.021","volume":"13","author":"Q Pei","year":"2023","unstructured":"Pei Q, Jiang B, Hao D, Xie Z (2023) Self-assembled nanoformulations of paclitaxel for enhanced cancer theranostics. Acta Pharm Sin B 13:3252\u20133276. https:\/\/doi.org\/10.1016\/j.apsb.2023.02.021","journal-title":"Acta Pharm Sin B"},{"key":"1609_CR128","doi-asserted-by":"publisher","first-page":"9250","DOI":"10.3390\/ijms22179250","volume":"22","author":"C Peloso","year":"2021","unstructured":"Peloso C, Trichet AP, Descotes J, Richard J, Roberge C, Lopez-Noriega A (2021) Evaluation of loco-regional skin toxicity induced by an in situ forming depot after a single subcutaneous injection at different volumes and flow rates in G\u00f6ttingen minipigs. Int J Mol Sci 22:9250. https:\/\/doi.org\/10.3390\/ijms22179250","journal-title":"Int J Mol Sci"},{"key":"1609_CR129","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Sabcs19-ot1-05-02","author":"TJ Pluard","year":"2020","unstructured":"Pluard TJ, Sharma P, Melisko ME, Vidula N, Weng DE, Skelton JD, Yoon KE, Cho HJ, Rugo HS (2020) Abstract OT1-05-02: a phase II study to evaluate the efficacy, safety and pharmacokinetics of DHP107 (Liporaxel\u00ae, oral paclitaxel) compared to IV paclitaxel in patients with recurrent or metastatic breast cancer: OPERA (NCT03326102). Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.Sabcs19-ot1-05-02"},{"key":"1609_CR130","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.84791","volume":"12","author":"AE Prota","year":"2023","unstructured":"Prota AE, Lucena-Agell D, Ma Y, Estevez-Gallego J, Li S, Bargsten K, Josa-Prado F, Altmann KH, Gaillard N, Kamimura S, M\u00fchlethaler T, Gago F, Oliva MA, Steinmetz MO, Fang WS, D\u00edaz JF (2023) Structural insight into the stabilization of microtubules by taxanes. Elife 12:e84791. https:\/\/doi.org\/10.7554\/eLife.84791","journal-title":"Elife"},{"key":"1609_CR131","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1002\/cncr.21227","volume":"104","author":"L Pusztai","year":"2005","unstructured":"Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, Symmans FW, Wong F, Blumenschein G, Fleming DR, Rouzier R, Boniface G, Hortobagyi GN (2005) Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 104:682\u2013691. https:\/\/doi.org\/10.1002\/cncr.21227","journal-title":"Cancer"},{"key":"1609_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.amolm.2024.100062","volume":"5","author":"M Qutub","year":"2025","unstructured":"Qutub M, Tatode A, Taksande J, Premchandani T, Umekar M, Hussain UM, Biyani D, Mane D (2025) Stimuli-responsive supramolecular hydrogels for paclitaxel delivery: progress and prospects. Aspects Mol Med 5:100062. https:\/\/doi.org\/10.1016\/j.amolm.2024.100062","journal-title":"Aspects Mol Med"},{"key":"1609_CR133","doi-asserted-by":"publisher","first-page":"v6","DOI":"10.1093\/annonc\/mdt322","volume":"24","author":"AA Ranade","year":"2013","unstructured":"Ranade AA, Joshi DA, Phadke GK, Patil PP, Kasbekar RB, Apte TG, Dasare RR, Mengde SD, Parikh PM, Bhattacharyya GS, Lopes GL (2013) Clinical and economic implications of the use of nanoparticle paclitaxel (Nanoxel) in India. Ann Oncol 24:v6\u2013v12. https:\/\/doi.org\/10.1093\/annonc\/mdt322","journal-title":"Ann Oncol"},{"key":"1609_CR134","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13163949","volume":"13","author":"F Rascio","year":"2021","unstructured":"Rascio F, Spadaccino F, Rocchetti MT, Castellano G, Stallone G, Netti GS, Ranieri E (2021) The pathogenic role of PI3K\/AKT pathway in cancer onset and drug resistance: an updated review. Cancers Basel 13:3949. https:\/\/doi.org\/10.3390\/cancers13163949","journal-title":"Cancers Basel"},{"key":"1609_CR135","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1158\/1535-7163.MCT-19-1095","volume":"19","author":"A Rau","year":"2020","unstructured":"Rau A, Lieb WS, Seifert O, Honer J, Birnstock D, Richter F, Aschmoneit N, Olayioye MA, Kontermann RE (2020) Inhibition of tumor cell growth and cancer stem cell expansion by a bispecific antibody targeting EGFR and HER3. Mol Cancer Ther 19:1474\u20131485. https:\/\/doi.org\/10.1158\/1535-7163.MCT-19-1095","journal-title":"Mol Cancer Ther"},{"key":"1609_CR136","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10585-013-9614-5","volume":"31","author":"DM Roque","year":"2013","unstructured":"Roque DM, Buza N, Glasgow M, Bellone S, Bortolomai I, Gasparrini S, Cocco E, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Santin AD (2013) Class III $\\beta$-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin\/paclitaxel. Clin Exp Metastasis 31:101\u2013110. https:\/\/doi.org\/10.1007\/s10585-013-9614-5","journal-title":"Clin Exp Metastasis"},{"key":"1609_CR137","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.clbc.2018.07.024","volume":"18","author":"HS Rugo","year":"2018","unstructured":"Rugo HS, Roche H, Thomas E, Chung HC, Lerzo GL, Vasyutin I, Patel A, Vahdat L (2018) Efficacy and safety of ixabepilone and capecitabine in patients with advanced triple-negative breast cancer: a pooled analysis from two large phase III, randomized clinical trials. Clin Breast Cancer 18:489\u2013497. https:\/\/doi.org\/10.1016\/j.clbc.2018.07.024","journal-title":"Clin Breast Cancer"},{"key":"1609_CR138","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Sabcs20-ps13-16","author":"HS Rugo","year":"2021","unstructured":"Rugo HS, Pluard TJ, Sharma P, Melisko M, Al-Jazayrly G, Vidula N, Ji Y, Weng D, Lim HS, Yoon KE, Cho HJ (2021) Pharmacokinetic evaluation of an oral paclitaxel DHP107 (Liporaxel\u00ae) in patients with recurrent or metastatic breast cancer (MBC): phase II study (OPERA, NCT03326102). Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.Sabcs20-ps13-16"},{"key":"1609_CR139","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1200\/jco.21.02953","volume":"41","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Umanzor GA, Barrios FJ, Vasallo RH, Chivalan MA, Bejarano S, Ram\u00edrez JR, Fein L, Kowalyszyn RD, Kramer ED, Wang H, Kwan MFR, Cutler DL (2023) Open-label, randomized, multicenter, phase III study comparing oral paclitaxel plus encequidar versus intravenous paclitaxel in patients with metastatic breast cancer. J Clin Oncol 41:65\u201374. https:\/\/doi.org\/10.1200\/jco.21.02953","journal-title":"J Clin Oncol"},{"key":"1609_CR140","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1846","volume":"15","author":"M Sarkar","year":"2023","unstructured":"Sarkar M, Wang Y, Ekpenyong O, Liang D, Xie H (2023) Pharmacokinetic behaviors of soft nanoparticulate formulations of chemotherapeutics. Wires Nanomed Nanobiotechnol 15:e1846. https:\/\/doi.org\/10.1002\/wnan.1846","journal-title":"Wires Nanomed Nanobiotechnol"},{"key":"1609_CR141","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1056\/nejmoa011954","volume":"346","author":"JH Schiller","year":"2002","unstructured":"Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92\u201398. https:\/\/doi.org\/10.1056\/nejmoa011954","journal-title":"N Engl J Med"},{"key":"1609_CR143","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd4811","volume":"13","author":"CM Scribano","year":"2021","unstructured":"Scribano CM, Wan J, Esbona K, Tucker JB, Lasek A, Zhou AS, Zasadil LM, Molini R, Fitzgerald J, Lager AM, Laffin JJ, Correia-Staudt K, Wisinski KB, Tevaarwerk AJ, O\u2019Regan R, McGregor SM, Fowler AM, Chappell RJ, Bugni TS, Burkard ME, Weaver BA (2021) Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel. Sci Transl Med 13:eabd4811. https:\/\/doi.org\/10.1126\/scitranslmed.abd4811","journal-title":"Sci Transl Med"},{"key":"1609_CR144","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2147\/tcrm.1.2.107.62910","volume":"1","author":"CD Scripture","year":"2005","unstructured":"Scripture CD, Figg WD, Sparreboom A (2005) Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy. Ther Clin Risk Manag 1:107\u2013114. https:\/\/doi.org\/10.2147\/tcrm.1.2.107.62910","journal-title":"Ther Clin Risk Manag"},{"key":"1609_CR145","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1127623","volume":"14","author":"AF Serpico","year":"2023","unstructured":"Serpico AF, Pisauro C, Grieco D (2023) cGAS-dependent proinflammatory and immune homeostatic effects of the microtubule-targeting agent paclitaxel. Front Immunol 14:1127623. https:\/\/doi.org\/10.3389\/fimmu.2023.1127623","journal-title":"Front Immunol"},{"key":"1609_CR146","doi-asserted-by":"publisher","first-page":"559","DOI":"10.52586\/s559","volume":"13","author":"P Seshadri","year":"2021","unstructured":"Seshadri P, Deb B, Kumar P (2021) Multifarious targets beyond microtubules\u2014role of eribulin in cancer therapy. Front Biosci (Schol Ed) 13:559\u2013573. https:\/\/doi.org\/10.52586\/s559","journal-title":"Front Biosci (Schol Ed)"},{"key":"1609_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114036","volume":"385","author":"S Seyam","year":"2025","unstructured":"Seyam S, Alallam B, Harif Fadzilah N, Abd Kadir E (2025) Advances in paclitaxel nanoformulations: a systematic review of in vivo therapeutic efficacy and safety enhancements. J Control Release 385:114036. https:\/\/doi.org\/10.1016\/j.jconrel.2025.114036","journal-title":"J Control Release"},{"key":"1609_CR148","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13045-025-01691-5","volume":"18","author":"M Shen","year":"2025","unstructured":"Shen M, Jiang X, Peng Q, Oyang L, Ren Z, Wang J, Peng M, Zhou Y, Deng X, Liao Q (2025) The cGAS-STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications. J Hematol Oncol 18:67. https:\/\/doi.org\/10.1186\/s13045-025-01691-5","journal-title":"J Hematol Oncol"},{"key":"1609_CR149","first-page":"823","volume":"56","author":"DM Silva","year":"2015","unstructured":"Silva DM, Franciosi AI, Pezzini PC, Guerios SD (2015) Subcutaneous administration of paclitaxel in dogs with cancer: a preliminary study. Can Vet J 56:823\u2013830","journal-title":"Can Vet J"},{"key":"1609_CR150","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jconrel.2005.09.033","volume":"109","author":"JW Singer","year":"2005","unstructured":"Singer JW (2005) Paclitaxel poliglumex (XYOTAX\u2122, CT-2103): a macromolecular taxane. J Control Release 109:120\u2013126. https:\/\/doi.org\/10.1016\/j.jconrel.2005.09.033","journal-title":"J Control Release"},{"key":"1609_CR151","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/j.clinthera.2013.10.009","volume":"35","author":"M Slingerland","year":"2013","unstructured":"Slingerland M, Guchelaar HJ, Rosing H, Scheulen ME, van Warmerdam LJ, Beijnen JH, Gelderblom H (2013) Bioequivalence of liposome-entrapped paclitaxel easy-to-use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: a randomized, two-period crossover study in patients with advanced cancer. Clin Ther 35:1946\u20131954. https:\/\/doi.org\/10.1016\/j.clinthera.2013.10.009","journal-title":"Clin Ther"},{"key":"1609_CR152","doi-asserted-by":"publisher","first-page":"31","DOI":"10.46439\/cancerbiology.2.031","volume":"2","author":"ER Smith","year":"2021","unstructured":"Smith ER, Xu XX (2021) Breaking malignant nuclei as a non-mitotic mechanism of Taxol-paclitaxel. J Cancer Biol 2:31\u201338. https:\/\/doi.org\/10.46439\/cancerbiology.2.031","journal-title":"J Cancer Biol"},{"key":"1609_CR153","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1021\/acs.jmedchem.0c01826","volume":"64","author":"MP Smolinski","year":"2021","unstructured":"Smolinski MP, Urgaonkar S, Pitzonka L, Cutler M, Lee G, Suh KH, Lau JYN (2021) Discovery of encequidar, first-in-class intestine specific P-glycoprotein inhibitor. J Med Chem 64:3677\u20133693. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01826","journal-title":"J Med Chem"},{"key":"1609_CR154","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.addr.2017.02.003","volume":"22","author":"AM Sofias","year":"2017","unstructured":"Sofias AM, Dunne M, Storm G, Allen C (2017) The battle of \u201cnano\u201d paclitaxel. Adv Drug Deliv Rev 22:20\u201330. https:\/\/doi.org\/10.1016\/j.addr.2017.02.003","journal-title":"Adv Drug Deliv Rev"},{"key":"1609_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.145117","volume":"318","author":"A Somaida","year":"2025","unstructured":"Somaida A, Abdelsalam AM, Khedr SM, Mohamed AM, Tariq I, Almohsen N, Ashraf O, Osman SK, Al-Sawahli MM, Engelhardt K, Bakowsky U (2025) Improved oral bioavailability of paclitaxel through folate-engineered zein nanoparticles: evaluation in intestinal organoid and in vivo models. Int J Biol Macromol 318:145117. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.145117","journal-title":"Int J Biol Macromol"},{"key":"1609_CR156","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ijpharm.2016.08.013","volume":"514","author":"R Soundararajan","year":"2016","unstructured":"Soundararajan R, Sasaki K, Godfrey L, Odunze U, Fereira N, Sch\u00e4tzlein A, Uchegbu I (2016) Direct in vivo evidence on the mechanism by which nanoparticles facilitate the absorption of a water insoluble, P-gp substrate. Int J Pharm 514:121\u2013132. https:\/\/doi.org\/10.1016\/j.ijpharm.2016.08.013","journal-title":"Int J Pharm"},{"issue":"20","key":"1609_CR157","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1200\/JCO.2009.24.4244","volume":"28","author":"JA Sparano","year":"2010","unstructured":"Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, Da Costa SC, Ro J, Rubio G, Rondinon M, Perez Manga G, Peck R, Poulart V, Conte P (2010) Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 28(20):3256\u20133263. https:\/\/doi.org\/10.1200\/JCO.2009.24.4244","journal-title":"J Clin Oncol"},{"key":"1609_CR158","first-page":"1937","volume":"4","author":"A Sparreboom","year":"1998","unstructured":"Sparreboom A, Verweij J, van der Burg ME, Loos WJ, Brouwer E, Vigano L, Locatelli A, de Vos AI, Nooter K, Stoter G, Gianni L (1998) Disposition of CrEL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. Clin Cancer Res 4:1937\u20131942","journal-title":"Clin Cancer Res"},{"key":"1609_CR159","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1590\/s1984-82502012000300002","volume":"48","author":"KMR Srivalli","year":"2012","unstructured":"Srivalli KMR, Lakshmi PK (2012) Overview of P-glycoprotein inhibitors: a rational outlook. Braz J Pharm Sci 48:353\u2013367. https:\/\/doi.org\/10.1590\/s1984-82502012000300002","journal-title":"Braz J Pharm Sci"},{"key":"1609_CR160","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40262-017-0563-z","volume":"57","author":"TB Stage","year":"2018","unstructured":"Stage TB, Bergmann TK, Kroetz DL (2018) Clinical pharmacokinetics of paclitaxel monotherapy: an updated literature review. Clin Pharmacokinet 57:7\u201319. https:\/\/doi.org\/10.1007\/s40262-017-0563-z","journal-title":"Clin Pharmacokinet"},{"key":"1609_CR161","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.1158\/1078-0432.Ccr-07-4738","volume":"14","author":"S Strieth","year":"2008","unstructured":"Strieth S, Eichhorn ME, Werner A, Sauer B, Teifel M, Michaelis U, Berghaus A, Dellian M (2008) Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with cisplatin. Clin Cancer Res 14:4603\u20134611. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-07-4738","journal-title":"Clin Cancer Res"},{"key":"1609_CR162","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.783317","volume":"12","author":"M Sui","year":"2021","unstructured":"Sui M, Yang H, Guo M, Li W, Gong Z, Jiang J, Li P (2021) Cajanol sensitizes A2780\/Taxol cells to paclitaxel by inhibiting the PI3K\/Akt\/NF-kappaB signaling pathway. Front Pharmacol 12:783317. https:\/\/doi.org\/10.3389\/fphar.2021.783317","journal-title":"Front Pharmacol"},{"issue":"2","key":"1609_CR163","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1854","volume":"15","author":"B Sun","year":"2023","unstructured":"Sun B, Lovell JF, Zhang Y (2023) Current development of cabazitaxel drug delivery systems. Wires Nanomed Nanobiotechnol 15(2):e1854. https:\/\/doi.org\/10.1002\/wnan.1854","journal-title":"Wires Nanomed Nanobiotechnol"},{"key":"1609_CR164","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.123899","volume":"654","author":"X Sun","year":"2024","unstructured":"Sun X, Lv G, Xiong J, Zhao J, Zhao J, Wang Z, Wang Y, Yin T, Gou J, He H, Tang X, Zhang Y (2024) Novel solid self-emulsifying drug delivery system to enhance oral bioavailability of cabazitaxel. Int J Pharm 654:123899. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.123899","journal-title":"Int J Pharm"},{"key":"1609_CR165","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s44174-025-00479-y","volume":"1","author":"N Sunstrom","year":"2025","unstructured":"Sunstrom N, Sunstrum FN (2025) Wearable devices for subcutaneous delivery of large-volume biologics: design, use, and regulatory perspective. Biomed Mater Devices 1:479\u2013485. https:\/\/doi.org\/10.1007\/s44174-025-00479-y","journal-title":"Biomed Mater Devices"},{"key":"1609_CR166","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.tox.2005.07.023","volume":"216","author":"J Szebeni","year":"2005","unstructured":"Szebeni J (2005) Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 216:106\u2013121. https:\/\/doi.org\/10.1016\/j.tox.2005.07.023","journal-title":"Toxicology"},{"key":"1609_CR167","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1254\/jphs.FP0040603","volume":"97","author":"R Taniguchi","year":"2005","unstructured":"Taniguchi R, Kumai T, Matsumoto N, Watanabe M, Kamio K, Suzuki S, Kobayashi S (2005) Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4. J Pharmacol Sci 97:83\u201390. https:\/\/doi.org\/10.1254\/jphs.FP0040603","journal-title":"J Pharmacol Sci"},{"key":"1609_CR169","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1023\/a:1025412509730","volume":"21","author":"AJ ten Tije","year":"2003","unstructured":"ten Tije AJ, Synold TW, Spicer D, Verweij J, Doroshow JH, Sparreboom A (2003) Effect of valspodar on the pharmacokinetics of unbound paclitaxel. Invest New Drugs 21:291\u2013298. https:\/\/doi.org\/10.1023\/a:1025412509730","journal-title":"Invest New Drugs"},{"key":"1609_CR170","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/107327480301000207","volume":"10","author":"H Thomas","year":"2017","unstructured":"Thomas H, Coley HM (2017) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 10:159\u2013165. https:\/\/doi.org\/10.1177\/107327480301000207","journal-title":"Cancer Control"},{"issue":"17","key":"1609_CR171","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1007\/s40265-015-0489-4","volume":"75","author":"M Trendowski","year":"2015","unstructured":"Trendowski M (2015) Recent advances in the development of antineoplastic agents derived from natural products. Drugs 75(17):1993\u20132016. https:\/\/doi.org\/10.1007\/s40265-015-0489-4","journal-title":"Drugs"},{"key":"1609_CR172","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17010063","volume":"17","author":"P Uttreja","year":"2025","unstructured":"Uttreja P, Karnik I, Adel Ali Youssef A, Narala N, Elkanayati RM, Baisa S, Alshammari ND, Banda S, Vemula SK, Repka MA (2025) Self-emulsifying drug delivery systems (SEDDS): transition from liquid to solid\u2014a comprehensive review of formulation, characterization, applications, and future trends. Pharmaceutics 17:63. https:\/\/doi.org\/10.3390\/pharmaceutics17010063","journal-title":"Pharmaceutics"},{"issue":"22","key":"1609_CR173","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P van Hagen","year":"2012","unstructured":"van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A, Group C (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366(22):2074\u20132084. https:\/\/doi.org\/10.1056\/NEJMoa1112088","journal-title":"N Engl J Med"},{"key":"1609_CR174","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ygyno.2019.11.034","volume":"156","author":"I Vergote","year":"2020","unstructured":"Vergote I, Bergfeldt K, Franquet A, Lisyanskaya AS, Bjermo H, Heldring N, Buyse M, Brize A (2020) A randomized phase III trial in patients with recurrent platinum sensitive ovarian cancer comparing efficacy and safety of paclitaxel micellar and CrEL-paclitaxel. Gynecol Oncol 156:293\u2013300. https:\/\/doi.org\/10.1016\/j.ygyno.2019.11.034","journal-title":"Gynecol Oncol"},{"issue":"7","key":"1609_CR175","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.ejca.2011.01.001","volume":"47","author":"C Villanueva","year":"2011","unstructured":"Villanueva C, Awada A, Campone M, Machiels JP, Besse T, Magherini E, Dubin F, Semiond D, Pivot X (2011) A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I\/II study. Eur J Cancer 47(7):1037\u20131045. https:\/\/doi.org\/10.1016\/j.ejca.2011.01.001","journal-title":"Eur J Cancer"},{"key":"1609_CR176","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2021.105812","volume":"162","author":"Z Vinarov","year":"2021","unstructured":"Vinarov Z, Abdallah M, Agundez JAG, Allegaert K, Basit AW, Braeckmans M, Ceulemans J, Corsetti M, Griffin BT, Grimm M, Keszthelyi D, Koziolek M, Madla CM, Matthys C, McCoubrey LE, Mitra A, Reppas C, Stappaerts J, Steenackers N, Trevaskis NL, Vanuytsel T, Vertzoni M, Weitschies W, Wilson C, Augustijns P (2021) Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: an UNGAP review. Eur J Pharm Sci 162:105812. https:\/\/doi.org\/10.1016\/j.ejps.2021.105812","journal-title":"Eur J Pharm Sci"},{"key":"1609_CR177","doi-asserted-by":"publisher","first-page":"143","DOI":"10.4137\/bcbcr.S5857","volume":"5","author":"P Vishnu","year":"2011","unstructured":"Vishnu P, Roy V (2011) Safety and efficacy of nab-paclitaxel in the treatment of patients with breast cancer. Breast Cancer Auckl 5:143\u2013152. https:\/\/doi.org\/10.4137\/bcbcr.S5857","journal-title":"Breast Cancer Auckl"},{"key":"1609_CR178","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/nejmoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691\u20131703. https:\/\/doi.org\/10.1056\/nejmoa1304369","journal-title":"N Engl J Med"},{"key":"1609_CR179","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.2147\/dddt.S64940","volume":"8","author":"P Vrignaud","year":"2014","unstructured":"Vrignaud P, Benning V, Beys E, Gupta S, Semiond D, Bouchard H (2014) Preclinical profile of cabazitaxel. Drug des Devel Ther 8:2009\u20132019. https:\/\/doi.org\/10.2147\/dddt.S64940","journal-title":"Drug des Devel Ther"},{"key":"1609_CR180","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1002\/1097-0142(20000601)88:11<2619::Aid-cncr26>3.0.Co;2-j","volume":"88","author":"TH Wang","year":"2000","unstructured":"Wang TH, Wang HS, Soong YK (2000) Paclitaxel-induced cell death. Cancer 88:2619\u20132628. https:\/\/doi.org\/10.1002\/1097-0142(20000601)88:11%3c2619::Aid-cncr26%3e3.0.Co;2-j","journal-title":"Cancer"},{"key":"1609_CR181","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jconrel.2017.09.026","volume":"267","author":"F Wang","year":"2017","unstructured":"Wang F, Porter M, Konstantopoulos A, Zhang P, Cui H (2017) Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy. J Control Release 267:100\u2013118. https:\/\/doi.org\/10.1016\/j.jconrel.2017.09.026","journal-title":"J Control Release"},{"key":"1609_CR182","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1080\/17460441.2022.2131766","volume":"17","author":"C Wang","year":"2022","unstructured":"Wang C, Aguilar A, Ojima I (2022) Strategies for the drug discovery and development of taxane anticancer therapeutics. Expert Opin Drug Discov 17:1193\u20131207. https:\/\/doi.org\/10.1080\/17460441.2022.2131766","journal-title":"Expert Opin Drug Discov"},{"key":"1609_CR183","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2204621120","volume":"120","author":"F Wang","year":"2023","unstructured":"Wang F, Huang Q, Su H, Sun M, Wang Z, Chen Z, Zheng M, Chakroun RW, Monroe MK, Chen D, Wang Z, Gorelick N, Serra R, Wang H, Guan Y, Suk JS, Tyler B, Brem H, Hanes J, Cui H (2023) Self-assembling paclitaxel-mediated stimulation of tumor-associated macrophages for postoperative treatment of glioblastoma. Proc Natl Acad Sci U S A 120:e2204621120. https:\/\/doi.org\/10.1073\/pnas.2204621120","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1609_CR184","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.3390\/ijms25073645","volume":"25","author":"X Wang","year":"2024","unstructured":"Wang X, Li D, Li G, Chen J, Yang Y, Bian L, Zhou J, Wu Y, Chen Y (2024) Enhanced therapeutic potential of hybrid exosomes loaded with paclitaxel for cancer therapy. Int J Mol Sci 25:3645. https:\/\/doi.org\/10.3390\/ijms25073645","journal-title":"Int J Mol Sci"},{"key":"1609_CR185","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1038\/s43018-025-01029-7","volume":"6","author":"Z Wang","year":"2025","unstructured":"Wang Z, Li W, Jiang Y, Ma T, Li M, Wu S, Tran TB, Cordova LE, Lin E, Scott AJ, Erdrich J, Schroeder J, Chalasani P, Lu J (2025) A sphingolipid-derived paclitaxel nanovesicle enhances efficacy of combination therapies in triple-negative breast cancer and pancreatic cancer. Nat Cancer 6:1734\u20131753. https:\/\/doi.org\/10.1038\/s43018-025-01029-7","journal-title":"Nat Cancer"},{"key":"1609_CR186","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/s0169-409x(97)00041-0","volume":"27","author":"P Watkins","year":"1997","unstructured":"Watkins P (1997) The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 27:161\u2013170. https:\/\/doi.org\/10.1016\/s0169-409x(97)00041-0","journal-title":"Adv Drug Deliv Rev"},{"key":"1609_CR187","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1091\/mbc.e14-04-0916","volume":"25","author":"BA Weaver","year":"2014","unstructured":"Weaver BA, Bement W (2014) How Taxol\/paclitaxel kills cancer cells. Mol Biol Cell 25:2677\u20132681. https:\/\/doi.org\/10.1091\/mbc.e14-04-0916","journal-title":"Mol Biol Cell"},{"key":"1609_CR188","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ijrobp.2013.02.009","volume":"86","author":"ME Werner","year":"2013","unstructured":"Werner ME, Cummings ND, Sethi M, Wang EC, Sukumar R, Moore DT, Wang AZ (2013) Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer. Int J Radiat Oncol Biol Phys 86:463\u2013468. https:\/\/doi.org\/10.1016\/j.ijrobp.2013.02.009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1609_CR189","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1021\/acs.molpharmaceut.9b00459","volume":"16","author":"A Wilson","year":"2019","unstructured":"Wilson A, Urquhart BL, Ponich T, Chande N, Gregor JC, Beaton M, Kim RB (2019) Crohn\u2019s disease is associated with decreased CYP3A4 and P-glycoprotein protein expression. Mol Pharm 16:4059\u20134064. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b00459","journal-title":"Mol Pharm"},{"key":"1609_CR190","doi-asserted-by":"publisher","first-page":"5650","DOI":"10.3390\/cancers13225650","volume":"13","author":"L Wordeman","year":"2021","unstructured":"Wordeman L, Vicente JJ (2021) Microtubule targeting agents in disease: classic drugs, novel roles. Cancers 13:5650. https:\/\/doi.org\/10.3390\/cancers13225650","journal-title":"Cancers"},{"key":"1609_CR191","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.apsb.2014.03.002","volume":"4","author":"H Wu","year":"2014","unstructured":"Wu H, Long X, Yuan F, Chen L, Pan S, Liu Y, Stowell Y, Li X (2014) Combined use of phospholipid complexes and self-emulsifying microemulsions for improving the oral absorption of a BCS class IV compound, baicalin. Acta Pharm Sin B 4:217\u2013226. https:\/\/doi.org\/10.1016\/j.apsb.2014.03.002","journal-title":"Acta Pharm Sin B"},{"key":"1609_CR192","doi-asserted-by":"publisher","DOI":"10.1007\/s44395-025-00012-6","volume":"1","author":"A Wu","year":"2025","unstructured":"Wu A, Rutland B, Southworth C, Bosshard J, Wall D (2025) The transformative potential of large-volume subcutaneous drug delivery: a discussion of current capabilities and future prospects for pharmaceutical manufacturers. Discov Pharm Sci 1:12. https:\/\/doi.org\/10.1007\/s44395-025-00012-6","journal-title":"Discov Pharm Sci"},{"key":"1609_CR193","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.7314\/apjcp.2013.14.4.2591","volume":"14","author":"X Xu","year":"2013","unstructured":"Xu X, Wang L, Xu HQ, Huang XE, Qian YD, Xiang J (2013) Clinical comparison between paclitaxel liposome (Lipusu (R)) and paclitaxel for treatment of patients with metastatic gastric cancer. Asian Pac J Cancer Prev 14:2591\u20132594. https:\/\/doi.org\/10.7314\/apjcp.2013.14.4.2591","journal-title":"Asian Pac J Cancer Prev"},{"key":"1609_CR194","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/jco.24.01888","volume":"43","author":"T Yamashita","year":"2025","unstructured":"Yamashita T, Saji S, Takano T, Naito Y, Tsuneizumi M, Yoshimura A, Takahashi M, Tsurutani J, Iwatani T, Kitada M, Tada H, Mori N, Higuchi T, Iwasa T, Araki K, Koizumi K, Hasegawa H, Uchida Y, Morita S, Masuda N (2025) Trastuzumab-pertuzumab plus eribulin or taxane as first-line chemotherapy for human epidermal growth factor 2\u2013positive locally advanced\/metastatic breast cancer: the randomized noninferiority phase III EMERALD trial. J Clin Oncol 43:1302\u20131313. https:\/\/doi.org\/10.1200\/jco.24.01888","journal-title":"J Clin Oncol"},{"key":"1609_CR195","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.3390\/molecules20034337","volume":"20","author":"FH Yang","year":"2015","unstructured":"Yang FH, Zhang Q, Liang QY, Wang SQ, Zhao BX, Wang YT, Cai Y, Li GF (2015) Bioavailability enhancement of paclitaxel via a novel oral drug delivery system: paclitaxel-loaded glycyrrhizic acid micelles. Molecules 20:4337\u20134356. https:\/\/doi.org\/10.3390\/molecules20034337","journal-title":"Molecules"},{"key":"1609_CR196","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4236\/jct.2025.161001","volume":"16","author":"VSNR Yendapalli","year":"2025","unstructured":"Yendapalli VSNR, Williams K, Oroszi T (2025) Role of P-Gp in treatment of cancer. J Cancer Ther 16:1\u201317. https:\/\/doi.org\/10.4236\/jct.2025.161001","journal-title":"J Cancer Ther"},{"key":"1609_CR197","doi-asserted-by":"publisher","DOI":"10.3390\/gels11070520","volume":"11","author":"MS Yoon","year":"2025","unstructured":"Yoon MS, Lee JM, Jo MJ, Kang SJ, Yoo MK, Park SY, Bong S, Park CS, Park CW, Kim JS, Han SB, Lee HJ, Shin DH (2025) Dual-drug delivery systems using hydrogel\u2013nanoparticle composites: recent advances and key applications. Gels 11:520. https:\/\/doi.org\/10.3390\/gels11070520","journal-title":"Gels"},{"key":"1609_CR198","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16060768","volume":"16","author":"M Yousef","year":"2024","unstructured":"Yousef M, O\u2019Croinin C, Le TS, Park C, Zuo J, Bou Chacra N, Davies NM, L\u00f6benberg R (2024) In vitro predictive model for intestinal lymphatic uptake: exploration of additional enhancers and inhibitors. Pharmaceutics 16:768. https:\/\/doi.org\/10.3390\/pharmaceutics16060768","journal-title":"Pharmaceutics"},{"key":"1609_CR199","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70097","volume":"6","author":"Y Yu","year":"2025","unstructured":"Yu Y, Wang Y, Mao L, Ye S, Lai X, Chen J, Zhang Y, Liu J, Wu J, Qin T, Yao H (2025) Phase I clinical trial to assess safety and efficacy of Oraxol, a novel oral paclitaxel chemotherapy agent, in patients with previously treated metastatic breast cancer. MedComm 6:e70097. https:\/\/doi.org\/10.1002\/mco2.70097","journal-title":"MedComm"},{"key":"1609_CR200","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ejpb.2012.04.001","volume":"81","author":"V Zabaleta","year":"2012","unstructured":"Zabaleta V, Ponchel G, Salman H, Ag\u00fceros M, Vauthier C, Irache JM (2012) Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: permeability and pharmacokinetic study. Eur J Pharm Biopharm 81:514\u2013523. https:\/\/doi.org\/10.1016\/j.ejpb.2012.04.001","journal-title":"Eur J Pharm Biopharm"},{"key":"1609_CR201","first-page":"6","volume":"3","author":"M Zaid","year":"2024","unstructured":"Zaid M, Kalam I, Majaz Q (2024) Gastro retentive drug delivery system. Int J Res Pharm Allied Sci 3:6\u201316","journal-title":"Int J Res Pharm Allied Sci"},{"key":"1609_CR202","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007965","volume":"6","author":"LM Zasadil","year":"2014","unstructured":"Zasadil LM, Andersen KA, Yeum D, Rocque GB, Wilke LG, Tevaarwerk AJ, Raines RT, Burkard ME, Weaver BA (2014) Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles. Sci Transl Med 6:219ra10. https:\/\/doi.org\/10.1126\/scitranslmed.3007965","journal-title":"Sci Transl Med"},{"key":"1609_CR203","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ejpb.2004.06.009","volume":"59","author":"JA Zhang","year":"2005","unstructured":"Zhang JA, Anyarambhatla G, Ma L, Ugwu S, Xuan T, Sardone T, Ahmad I (2005) Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm 59:177\u2013187. https:\/\/doi.org\/10.1016\/j.ejpb.2004.06.009","journal-title":"Eur J Pharm Biopharm"},{"key":"1609_CR204","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1016\/j.apsb.2020.12.022","volume":"11","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Lu Y, Qi J, Wu W (2021) An update on oral drug delivery via intestinal lymphatic transport. Acta Pharm Sin B 11:2449\u20132468. https:\/\/doi.org\/10.1016\/j.apsb.2020.12.022","journal-title":"Acta Pharm Sin B"},{"key":"1609_CR205","doi-asserted-by":"publisher","first-page":"26690","DOI":"10.1021\/acsnano.4c06399","volume":"18","author":"B Zhang","year":"2024","unstructured":"Zhang B, Zhou S, Lu S, Xiang X, Yao X, Lei W, Pei Q, Xie Z, Chen X (2024) Paclitaxel prodrug enables glutathione depletion to boost cancer treatment. ACS Nano 18:26690\u201326703. https:\/\/doi.org\/10.1021\/acsnano.4c06399","journal-title":"ACS Nano"},{"key":"1609_CR206","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1146\/annurev-immunol-101721-032910","volume":"43","author":"B Zhang","year":"2025","unstructured":"Zhang B, Xu P, Ablasser A (2025a) Regulation of the cGAS-STING pathway. Annu Rev Immunol 43:667\u2013692. https:\/\/doi.org\/10.1146\/annurev-immunol-101721-032910","journal-title":"Annu Rev Immunol"},{"key":"1609_CR207","doi-asserted-by":"publisher","DOI":"10.3390\/ph18020262","volume":"18","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Shang H, Zhang J, Jiang Y, Li J, Xiong H, Chao T (2025b) Drug treatment direction based on the molecular mechanism of breast cancer brain metastasis. Pharmaceuticals Basel 18:262. https:\/\/doi.org\/10.3390\/ph18020262","journal-title":"Pharmaceuticals Basel"},{"key":"1609_CR208","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2021.105992","volume":"167","author":"D Zhao","year":"2021","unstructured":"Zhao D, Hu C, Fu Q, Lv H (2021) Combined chemotherapy for triple negative breast cancer treatment by paclitaxel and niclosamide nanocrystals loaded thermosensitive hydrogel. Eur J Pharm Sci 167:105992. https:\/\/doi.org\/10.1016\/j.ejps.2021.105992","journal-title":"Eur J Pharm Sci"},{"key":"1609_CR209","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01731","volume":"10","author":"H Zhou","year":"2021","unstructured":"Zhou H, Yan J, Chen W, Yang J, Liu M, Zhang Y, Shen X, Ma Y, Hu X, Wang Y, Du K, Li G (2021) Population pharmacokinetics and exposure-safety relationship of paclitaxel liposome in patients with non-small cell lung cancer. Front Oncol 10:1731. https:\/\/doi.org\/10.3389\/fonc.2020.01731","journal-title":"Front Oncol"},{"key":"1609_CR210","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202412649","volume":"63","author":"X Zhou","year":"2024","unstructured":"Zhou X, Zhang P, Yang Y, Shi W, Liu L, Lai Z, Zhang X, Pan P, Li L, Du J, Qian H, Cui S (2024) Highly potent and intestine specific P-glycoprotein inhibitor to enable oral delivery of Taxol. Angew Chem Int Ed Engl 63:e2412649. https:\/\/doi.org\/10.1002\/anie.202412649","journal-title":"Angew Chem Int Ed Engl"}],"container-title":["Archives of Pharmacal Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-026-01609-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12272-026-01609-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-026-01609-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:03:29Z","timestamp":1777907009000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12272-026-01609-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":205,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1609"],"URL":"https:\/\/doi.org\/10.1007\/s12272-026-01609-w","relation":{"references":[{"id-type":"doi","id":"10.1158\/1538-7445.Sabcs19-ot1-05-02","asserted-by":"subject"},{"id-type":"doi","id":"10.1158\/1538-7445.Sabcs20-ps13-16","asserted-by":"subject"}]},"ISSN":["0253-6269","1976-3786"],"issn-type":[{"value":"0253-6269","type":"print"},{"value":"1976-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Im-Sook Song is an Associate Editor of this journal Archives of Pharmacal Research, but this position had no influence on the editorial decision or the peer review process of this manuscript. Other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This review paper does not involve any experimental research with human participants or animals performed by the authors. All data and information included in this study were sourced from previously published literature, databases, and publicly available resources, ensuring compliance with ethical guidelines. Proper citations have been provided for all referenced materials to acknowledge the contributions of original authors and avoid plagiarism. The authors affirm that this work complies with the ethical standards for academic publishing and adheres to the principles of integrity, transparency, and accountability in scientific communication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}